Planning Principles for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma demands a delineation approach that blends detailed physical examination with multimodal image fusion. Unlike many other head and neck sites, the proximity to skull base and neural pathways makes planning uniquely challenging — and any shortcut in imaging assessment carries a steep clinical cost.
Thorough endoscopic examination is mandatory. It should evaluate the anterior nasal space, nasopharynx, and oropharynx, documenting tumor extension and infiltration. In practice, many centers undervalue this step — yet correlating endoscopic findings with imaging data is precisely what prevents gross GTV errors.
Contrast-enhanced MRI is indispensable unless contraindicated (e.g., pacemaker). Ideally, the MRI should be acquired in treatment position with the immobilization device in place. T1-weighted non-contrast sequences are best for detecting bone marrow infiltration. For skull base delineation and perineural disease, MRI has no substitute.
PET/CT serves as a complementary guide. At the primary site, it may overestimate or underestimate true disease extent, particularly at the skull base. However, for identifying small lymph node metastases, PET/CT is extremely valuable. For a comprehensive overview, see our complete guide on target volume delineation and field setup.
Simulation and Patient Immobilization
Simulation is performed supine with head and neck in neutral position using a 5-point thermoplastic mask from skull vertex, with or without shoulders. The planning CT should use 2–3 mm slice thickness with IV contrast, typically acquired from vertex to 2 cm below the sternoclavicular joints.
Centers using beam split technique with low anterior neck AP or AP/PA fields for N0 patients can obtain thicker slices in the low neck. This practical flexibility reduces simulation time without compromising planning quality in the primary target region.
EBER status should be obtained from tissue biopsies to inform prognosis. When available, EBV DNA quantification via a CLIA-certified laboratory adds prognostic value.
Gross Disease Target Volumes
Target volumes include GTV (gross tumor volume) and CTV (clinical target volume). Accurate selection and delineation of the primary CTV and subclinical region are critical in the IMRT era for NPC, given the ease of tumor spread along neural pathways and foramina.
| Volume | Definition | Margin |
|---|---|---|
| GTV70 | All gross disease on physical examination and imaging. Scrutinize skull base invasion and perineural spread | — |
| GTV70 nodal | Nodes ≥1 cm short axis, necrotic center, or FDG-avid. When in doubt, contour as GTV | — |
| CTV70 primary | GTV70 primary + margin. When GTV is certain, CTV may equal GTV without additional margin | 3–5 mm |
| CTV70 nodal | GTV70 nodal + margin. For small nodes (~1 cm), 63–66 Gy may be considered | 3–5 mm |
| PTV70 primary | CTV70 primary + margin per daily setup. Accept PTV compromise near critical OARs | 3–5 mm |
| PTV70 nodal | CTV70 nodal + margin | 3 mm |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Table 1.1)
When tumor approaches the ipsilateral optic nerve, an informed risk-benefit discussion is essential. The authors favor full tumor coverage even at the expense of the ipsilateral optic apparatus, while strictly constraining the contralateral optic nerve and chiasm. A 0 mm margin is acceptable when tumor abuts critical OARs such as brainstem and spinal cord.
Suggested gross disease dose: 2–2.12 Gy/fraction to 69.96–70 Gy in 33–35 fractions.
High-Risk Subclinical Volumes
The high-risk subclinical CTV involves a 10 mm expansion from the primary GTV70 (when feasible), encompassing the entire nasopharynx. Coverage requirements depend on T-stage.
| Structure | Coverage | Condition |
|---|---|---|
| Soft palate | Inferiorly | Always |
| Posterior nasal cavity | ≥5 mm from choana | Always |
| Posterior maxillary sinuses | Pterygopalatine fossae (V2) | Always |
| Posterior ethmoid sinus | When indicated | If invaded |
| Skull base (foramen ovale, rotundum, lacerum) | Foramina | Always |
| Cavernous sinus to Meckel’s cave | Involved side | T3–T4 |
| Pterygoid fossa/parapharyngeal spaces | Complete | Always |
| Sphenoid sinus | Inferior half (T1–T2); whole (T3–T4) | Per T-stage |
| Clivus | 1/3 if no invasion; whole if invaded; when in doubt, target entire clivus | Per invasion |
Source: Target Volume Delineation and Field Setup, 2nd Edition (Table 1.2)
Reviewing bone windows during CT contouring is essential to ensure skull base foramina coverage. This step is often overlooked in practice — yet it can make the difference between adequate and failed coverage.
The nodal subclinical CTV should include bilateral retropharyngeal nodes and levels IB, II, III, IV, and V. Level IB can be omitted in N0 neck and, at clinician discretion, in N+ neck when no suspicious IB nodes are present. Omitting the low neck may be considered for N0 patients.
High-risk subclinical dose: 1.6–1.7 Gy/day for 35 fractions or 1.64–1.8 Gy/day for 33 fractions. Sequential (non-SIB) techniques are also viable, delivering 50–54 Gy to subclinical volumes with a 16–20 Gy boost to gross disease for a total of 70 Gy.
Adaptive Planning and Clinical Considerations
Nasopharyngeal carcinoma frequently benefits from adaptive replanning during treatment. For instance, cT3N2 patients may show significant tumor regression mid-course, allowing GTV reduction superiorly and improved clearance from critical structures like the optic chiasm.
Mid-treatment MRI simulation captures this regression and guides volume adjustments. Phase 1 typically uses broader volumes, while Phase 2 incorporates tumor response with a reduced GTV and better OAR sparing. The 56 Gy PTV should maintain microscopic disease coverage even as the superior GTV shrinks.
Near the brainstem, PTV dose compromise must be accepted to respect OAR tolerance — or PTV margin can be reduced to 0 mm. Posterior cervical level V coverage, including the trapezius muscle, deserves careful attention. Coverage of fat posterior to the clavicle may also be considered.
For alternative dosing, refer to the NRG HN001 protocol or international consensus guidelines for NPC CTV delineation (Lee et al., Radiother Oncol, 2018). For additional tumor sites and field setup details, visit our complete target volume delineation guide.
